Acasti Pharma, Inc. ( (GRCE) ) has released its Q1 earnings. Here is a breakdown of the information Acasti Pharma, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Grace Therapeutics, Inc., formerly known as Acasti Pharma, Inc., is a Delaware-based biopharmaceutical company focused on developing and commercializing products for rare and orphan diseases using novel drug delivery technologies.
In its latest quarterly earnings report for the period ending June 30, 2025, Grace Therapeutics highlighted its strategic focus on its lead product candidate, GTx-104, aimed at improving the management of hypotension in patients with aneurysmal subarachnoid hemorrhage. The company also reported a net loss and outlined its plans to secure additional funding to support its operations.
Key financial metrics from the report include a net loss of $3.36 million for the quarter, a decrease from the $2.62 million loss in the same period last year. Operating expenses were primarily driven by research and development costs, which were significantly reduced compared to the previous year, reflecting the company’s strategic realignment. Additionally, Grace Therapeutics completed a private placement in February 2025, raising $13.7 million to support its ongoing development efforts.
The company remains focused on advancing GTx-104 through the regulatory review process, with plans for pre-commercial planning and a potential product launch pending FDA approval. Grace Therapeutics also continues to explore strategic partnerships or licensing opportunities for its other drug candidates, GTx-102 and GTx-101.
Looking ahead, Grace Therapeutics is optimistic about its ability to sustain operations over the next 12 months with its current cash reserves. However, the company acknowledges the need for additional capital to achieve its long-term goals and is actively seeking further financing options to support its strategic initiatives.